---
schema_version: "secwatch.filing_event.v1"
accession: "0001438133-23-000094"
form_type: "8-K"
ticker: "TNDM"
cik: "0001438133"
company_name: "TANDEM DIABETES CARE INC"
filed_at: "2023-05-26T23:59:59+00:00"
generated_at: "2026-06-14T12:45:07.549454+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Tandem Diabetes annual meeting results: all director nominees elected, 2023 LTIP approved

## Summary
- Stockholders elected 7 directors; Blickenstaff, Cha, Howell, Malagueira, McGroddy-Goetz, Sheridan, Twomey.
- 2023 Long-Term Incentive Plan approved with 51.8M votes for, 4.1M against.
- Named executive officer compensation approved on advisory basis (45.7M for, 10.3M against).
- Ernst & Young ratified as auditor for FY2023 (58.1M for, 0.8M against).
- Deadline for Rule 14a-8 proposals for 2024 annual meeting: December 14, 2023.

## SEC filing metadata
- accession: 0001438133-23-000094
- form_type: 8-K
- ticker: TNDM
- cik: 0001438133
- company_name: TANDEM DIABETES CARE INC
- filed_at: 2023-05-26T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.07, 5.08
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438133/000143813323000094/0001438133-23-000094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438133/000143813323000094/tndm-20230524.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438133-23-000094
- JSON: https://secwatch.observer/filing/0001438133-23-000094.json
- Plain text: https://secwatch.observer/filing/0001438133-23-000094.txt

## Key facts
- Shareholder Votes
  TANDEM DIABETES CARE INC shareholders approved To ratify of the appointment of Ernst & Young LLP to serve as the Company's independent registered public accountant for the year ending December 31, 2023. at the 2023-05-24 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-24
  source text: Proposal 4 : To ratify of the appointment of Ernst & Young LLP to serve as the Company's independent registered public accountant for the year ending December 31, 2023. The proposal received the following votes: For Against Abstain Broker Non-Votes 58,058,014 790,996 65,483
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438133/000143813323000094/0001438133-23-000094-index.htm
- Shareholder Votes
  TANDEM DIABETES CARE INC shareholders approved To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. at the 2023-05-24 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-05-24
  source text: Proposal 3 : To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. The proposal received the following votes: For Against Abstain Broker Non-Votes 45,684,932 10,258,454 50,633 2,920,474
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438133/000143813323000094/0001438133-23-000094-index.htm
- Shareholder Votes
  TANDEM DIABETES CARE INC shareholders approved To approve the Company's 2023 Long-Term Incentive Plan, which will replace the 2013 Stock Incentive Plan expiring on November 15, 2023. at the 2023-05-24 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-05-24
  source text: Proposal 2 : To approve the Company's 2023 Long-Term Incentive Plan, which will replace the 2013 Stock Incentive Plan expiring on November 15, 2023. The proposal received the following votes: For Against Abstain Broker Non-Votes 51,791,463 4,104,680 97,876 2,920,474
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438133/000143813323000094/0001438133-23-000094-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.